Triolein Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 970

Clinical Trials

Several clinical trials involve triolein to evaluate conditions such as obesity, exocrine pancreatic insufficiency, atherosclerosis, and metabolic processes including oral fat perception, fecal lipid elimination, and vascular monocyte responses. Sponsored by academic centers—such as Washington University School of Medicine, Mayo Clinic, Corporacion Parc Tauli, and Imperial College London—alongside industry partners like GlaxoSmithKline, these studies feature unassigned or unspecified trial phases. Recorded recruitment statuses for these investigations include both completed and terminated trials.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03002168	COMPLETED	Healthy Participants	Mayo Clinic	2017-01-20
NCT02101346	TERMINATED	Atherosclerosis	Imperial College London	2014-10
NCT01128400	Completed	Obesity	Washington University School of Medicine\|GlaxoSmithKline	2010-05	--

(data from https://clinicaltrials.gov, updated on 2017-11-17)

Check the Triolein product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Triolein acts as an inhibitor of matrix metalloproteinase-1 (MMP-1), thereby suppressing downstream reactive oxygen species generation and downregulating interleukin-6 expression at the cellular level. By mitigating oxidative stress, tissue degradation, and inflammatory mediator signaling, this molecular activity provides a mechanistic rationale for clinical investigations into metabolic and vascular disorders such as obesity and atherosclerosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).